Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  ANTIBIOTICS
A Global Strategic Business Report

This report analyzes the worldwide markets for Antibiotics in US$ Billion. The Major product segments Analyzed are Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 205 companies including many key and niche players worldwide such as Abbott Laboratories, MiddleBrook™ Pharmaceuticals, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook™ Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., Toyama Chemical Co., Ltd., and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1705  PAGES:    694
PRICE:    $3950  DATE:       May 2008
COMPANIES:  205  MARKET DATA TABLES:   191
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  ANTIBIOTICS (Complete Report) Pages : 694   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS5$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3
Penicillin.....I-3
  
   Cephalosporins.....I-4
Macrolides.....I-4
Quinolones.....I-4
Carbapenems.....I-4
Other Antibiotics.....I-4
Aminoglycosides.....I-4
Tetracyclines.....I-4
Sulfonamides.....I-4
  
   Mupirocin.....I-5
Glycopeptides.....I-5
Synercid.....I-5
Oxazolidinones.....I-5
Linezolid.....I-5
  
II. EXECUTIVE SUMMARY83$2250
  1. Industry Overview.....II-11 $100  
   Antibiotic Resistance and Generic Competition to Impact Long Term Growth.....II-1
Current & Future Analysis.....II-1
1$100
  2. Market Dynamics.....II-23 $400  
   Anti-Bacterials Segment Drives Global Anti-Infectives Market.....II-2
Antibiotic Resistance – A Primary Growth Inhibitor.....II-2
Antibiotic-Resistant Bacteria by Type.....II-2
1$100
   Patent Expiries Commoditize Antibiotics.....II-3
Patent Expiries of Leading Drugs in the Recent Past, Current, and Future.....II-3
Anti-MRSA Antibiotics Find Their Way ......II-3
1$100
   Table 1: Estimated Revenues Generated by Leading MRSA Antibiotic Drugs in 2005 (includes corresponding Graph/Chart).....II-4
Key Antibiotics in Pipeline.....II-4
1$350
  3. Competition.....II-54 $900  
   Highly Competitive Market.....II-5
Table 2: Leading Players in the Worldwide Antibiotics Market (2006): Percentage Breakdown by Value Sales for Pfizer, Glaxo Smithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott, Wyeth, and Others (includes corresponding Graph/Chart).....II-5
GlaxoSmithKline – The Undisputed Leader of Penicillin Market.....II-5
1$350
   Table 3: Worldwide Leading Antibiotics within Penicillin Class (2005 & 2006): Percentage Breakdown by Value for Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes corresponding Graph/Chart).....II-6
GlaxoSmithKline Leads Cephalosporin Market.....II-6
Table 4: Worldwide Leading Antibiotics within Cephalosporin Class (2005 & 2006): Percentage Breakdown by Value for Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil, Cefzon, Flumarin, and Others (includes corresponding Graph/Chart).....II-6
1$350
   Pfizer Dominates Macrolides Market.....II-7
Table 5: Worldwide Leading Antibiotics within Macrolide Class (2005 & 2006): Percentage Breakdown by Value for Zithromax, Klaricid/Biaxin, Ketek, and Others (includes corresponding Graph/Chart).....II-7
Levaquin/Tavanic – The Most Preferred Quinolone Antibiotic.....II-7
Table 6: Worldwide Leading Antibiotics within Quinolone Class (2005 & 2006): Percentage Breakdown by Value for Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and Others (includes corresponding Graph/Chart).....II-7
1$350
   Merck Rules Carbapenems Market.....II-8
Table 7: Worldwide Leading Antibiotics within Carbapenem Class (2005 & 2006): Percentage Breakdown by Value for Primaxin, Merrem, Invanz, and Others (includes corresponding Graph/Chart).....II-8
1$350
  4. Product Overview.....II-910 $700  
   Antibiotics – An Introduction.....II-9
Antibiotic Resistance.....II-9
1$100
   ß –Lactams.....II-101$100
   Classification of Antibiotics.....II-11
Key Milestones in Antibiotic Development.....II-11
Antibiotic Types.....II-11
Penicillin.....II-11
History.....II-11
1$100
   About the Drug.....II-12
Cephalosporins.....II-12
Treatment.....II-12
1$100
   Effects of the Drug.....II-13
Macrolides.....II-13
Treatment.....II-13
Quinolones.....II-13
1$100
   Carbapenems.....II-14
Other Antibiotics.....II-14
Aminoglycosides.....II-14
Treatment.....II-14
1$100
   Effects of the Drug.....II-15
Tetracyclines.....II-15
Treatment.....II-15
1$100
   Effects of the Drug.....II-16
Sulfonamides.....II-16
Treatment.....II-16
1$100
   Effects of the Drug.....II-17
Mupirocin.....II-17
Glycopeptides.....II-17
Synercid.....II-17
1$100
   Oxazolidinones.....II-18
Linezolid.....II-18
1$100
  5. Research Findings.....II-191 $100  
   Cephalosporins Effective when Compared to Penicillin.....II-19
FDA Bans Baytril Antibiotic for Chickens.....II-19
Erythromycin Along with Some Specific Drugs Increase Risk of Sudden Death.....II-19
Rise in Usage of Quinolones for Urinary Tract Infections Leads to Drug
  Resistance.....II-19
1$100
  6. FDA Approvals/Patents.....II-206 $600  
   MiddleBrook Obtains NDA Approval for MOXATAG™.....II-20
J&JPRD Seeks FDA Approval for Doripenem Antibiotic.....II-20
J&JPRD Seeks FDA Approval for Investigational Antibiotic, Ceftobiprole.....II-20
GSK Receives Approval for ALTARGO® in Europe.....II-20
1$100
   APL Receives FDA Approval for Cefpodoxime Proxetil.....II-21
Cubist Receives Approval to Market CUBICIN in Canada.....II-21
Cubist Obtains Approval to Market CUBICIN for Added Indications in EU.....II-21
Cubist Gains Approval for CUBICIN in Taiwan and South Korea.....II-21
Cethromycin Achieves FDA’s Orphan Drug Designation.....II-21
1$100
   FDA Approves Wockhardt’s Cefotaxime Injection.....II-22
FDA Approves Doxycycline Tablets.....II-22
FDA Approves Clarithromycin.....II-22
FDA Approves Doxycycline Tablets For The US Market.....II-22
Johnson & Johnson Applies Doripenem For FDA Approval.....II-22
FDA Certifies Antibioticos do Brasil’s Plant.....II-22
FDA Certifies ANDA For Cefdinir Capsules.....II-22
1$100
   US FDA Approves Teva’s Cefprozil Tablets.....II-23
FDA Certifies ANDA for Cephalexin Capsules.....II-23
American Pharmaceutical Partners Receives FDA Approvals for Ceftriaxone for Injection,
  USP.....II-23
Advancis’s Keflex Receives FDA Approval.....II-23
Wockhardt Gains Marketing Approval for Cefuroxime axetil in the US.....II-23
Wyeth’s Mylotarq Receives Government’s Approval.....II-23
1$100
   FDA Approves Generic Version of Zithromax.....II-24
Pfizer Wins FDA Approval for Zmax™.....II-24
Venus Remedies Files Second PCT for New Cephalosporins.....II-24
Falcon Gains US FDA Approval for its Generic Anti-Infective Solution.....II-24
1$100
   Cadilla Receives FDA Approval to Market Clindamycin.....II-25
1$100
  7. Recent Industry Activity.....II-2621 $1100  
   3i to Buy Alpharma Unit.....II-26
NCPC to Acquire Stake in DSM’s Antibiotics Division.....II-26
ULL Establishes New Antibiotics Unit in Himachal Pradesh.....II-26
Biocat to Expand Presence in the Indian Market.....II-26
PRWT Acquires Cherokee Chemical Unit from Merck.....II-26
1$100
   CSPC Joins Hands with Indonesian Firms.....II-27
Nisshin-Kyorin to Merge with Kyorin Pharmaceutical.....II-27
Schering-Plough Acquires Organon BioSciences.....II-27
GSK & Anacor Partner for Boron Chemistry-Based Antibiotics and Antivirals.....II-27
1$100
   Iroko Bags Canadian Rights to Vancocin®.....II-28
Cubist Licenses CUBICIN Rights to Merck.....II-28
Sagent Partners with Astral to Develop Injectable Antibiotics.....II-28
MR Healthcare to Manufacture New Antibiotics & Medicines.....II-28
1$100
   Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo.....II-29
C&O Pharmaceutical to Distribute Meiact in China.....II-29
Bioton Signs Deal to Market Antibiotics in Russia.....II-29
Toyama Gains Marketing Approval for Geninax® in Japan.....II-29
Forest Laboratories Acquires Cerexa.....II-29
Oscient Modifies Licensing Agreement With LG Life Sciences.....II-29
1$100
   Orchid Sign Licensing & Distribution Pact With Actavis.....II-30
Forest Laboratories Revokes Partnership With Replidyne.....II-30
SRI and Blanca Collaborate To Develop & Test Carbacephem.....II-30
AstraZeneca To Expand Research Center For Antibiotics.....II-30
Jade Pharmaceutical Begins Levofloxacin’s Production in China.....II-30
1$100
   Reyoung To Start Antibiotic Production At New Facility.....II-31
Toyama Begins T-705 Clinical Trials.....II-31
SmPC For Sanofi-Aventis’ Ketek® Updated.....II-31
Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic Tablets in France.....II-31
Antibiotice Plans To Infuse Funds For Antibiotics Production.....II-31
UAE Approves Pfizer’s Zithromax SD.....II-31
Premier Takes Over Cereplex.....II-31
1$100
   Laboratorios Roemmers Acquires Argentine Pharmaceutical’s Business.....II-32
Ranbaxy Adds Be-Tabs.....II-32
AstraZeneca Purchases Vancocin® From Eli Lilly.....II-32
Ranbaxy Laboratories Limited Acquires Ethimed NV.....II-32
Ranbaxy Laboratories Limited Acquires Terapia SA.....II-32
1$100
   Ranbaxy Italia Acquires Allen Generic Business of GlaxoSmithKline.....II-33
Connetics Acquires Sales Organization of PediaMed.....II-33
Wyeth Increases Stake in Wyeth KK to 80%.....II-33
1$100
   Sankyo Pharma, Daiichi Medical Research and Daiichi Pharmaceutical Merge.....II-34
Merck & Co. and Paratek Sign Development & License Pact.....II-34
Wakunga and Rib-X Sign Licensing Pact.....II-34
Pfizer Settles Infringement Lawsuit With Teva.....II-34
Astellas Extends Agreement With Theravance.....II-34
1$100
   Astellas and Theravance Sign Collaboration Agreement.....II-35
Cubist and AstraZeneca Sign License Pact.....II-35
Astellas Pharma and Sanofi-Aventis Revoke Marketing Pact.....II-35
Achaogen Bags Licensing Agreement from Isis.....II-35
Pfizer Bags Rights from Oscient to Market Antibiotic in Mexico.....II-35
Replidyne Enters into Licensing Agreement with Forest Laboratories.....II-35
1$100
   Toyama Chemical Co Ltd Enters into Licensing Agreement with Astellas Pharma.....II-36
AVAS’ Majority Stake To Be Sold.....II-36
NIH Grants US$3 Million To PolyMedix For Antibiotics.....II-36
Wyeth’s Tygacil Achieves European Approval.....II-36
1$100
   Chiron’s Cubicin® Receives Marketing Grant In The EU.....II-37
Vietnam Bans Antibiotics In Aquaculture.....II-37
Sance Pharmaceuticals Establishes Sance Laboratories.....II-37
Caps Holdings Plans to Re-enter Penicillin Market.....II-37
Alkem Establishes Sterile Cephalosporin Unit.....II-37
Novartis Completes Chiron Acquisition.....II-37
Toyama Submits New Drug Application For Quinolone Antibiotic Compound.....II-37
1$100
   China Pharma Receives GMP Certification For Cephalosporin Antibiotic
  Production.....II-38
Venus Remedies Files For FDC Approval.....II-38
Sankyo Acquires rival Daiichi Pharmaceutical for US$ 7 Billion.....II-38
Daiichi Pharmaceutical Takes Over Daiichi Suntory Pharma.....II-38
Pfizer Acquires Idun Pharmaceuticals.....II-38
1$100
   Pfizer Acquires Vicuron Pharmaceuticals.....II-39
Pfizer Acquires Bioren.....II-39
Novartis Acquires Eon Labs.....II-39
1$100
   Kyorin Pharmaceutical Acquires Stake in Toyo Pharmar.....II-40
Targanta Acquires InterMune’s Late-Stage Antibiotic.....II-40
Novartis Acquires Hexal.....II-40
1$100
   TB Alliance and Bayer Partner in Clinical Trials.....II-41
SBC Communications Enters into Agreement with Pfizer for Managed Voice
  Services.....II-41
1$100
   Vicuron Extends Oral Antibiotics Development Agreement With Pfizer.....II-42
Orchid Chemicals Signs Distribution Agreement with Mayne Pharma.....II-42
Cubist Pharmaceuticals Inks Agreement with ACS Dobfar.....II-42
Orchid Chemicals Inks Marketing Agreement with Alpharma.....II-42
Lupin and DSM Anti-Infectives Sign Agreement to Market Cephalosporins.....II-42
1$100
   Ranbaxy to Market P&G’s Generic Drug.....II-43
Nectar Expands Capacity.....II-43
Novartis Establishes Novartis Holding Japan.....II-43
Sun Pharma Acquires Phlox Pharma.....II-43
Kyorin Takes Over ActivX.....II-43
Advancis Acquires Lilly’s Keflex Brand.....II-43
1$100
   Enanta Enters into Partnership with Shionogi & Co......II-44
Toyama Signs Collaborative Agreement with Glaxo to Develop Antibacterial
  Agents.....II-44
1$100
   Enanta and Shionogi Ink an Agreement to Market EP- 013420.....II-45
Orchid Inks Agreement with Apotex to Market Generic Antibiotics.....II-45
Toyama Signs Licensing Agreement for TN-3262a with Dong-A.....II-45
Toyama Inks License Agreement with Schering for T-3811.....II-45
1$100
   Shionogi Wins Rights to Market Cedax in the US.....II-46
Connetics Enters Acne Market.....II-46
1$100
  8. Product Innovations/Introductions.....II-476 $600  
   MIT Scientists Develop a New Antibiotic, Rhodostreptomycin.....II-47
Watson Pharma Introduces Biaxin XL’s Generic Version.....II-47
Toyama Launches New Garenoxacin Quinolone Antibiotic.....II-47
Wockhardt to Introduce Cefprozil in the US.....II-47
MSD India Launches Invanza in India.....II-47
1$100
   Orchid Chemicals to Introduce Three New Drugs in the US.....II-48
DUSA Pharmaceuticals Releases ClindaReach™.....II-48
Mylan Releases Cipro’s Generic Version.....II-48
Macrolide Antibiotic Developed In the US.....II-48
University of Michigan Devises NMR Spectroscopy For Antibiotics.....II-48
Glycopeptide-Cephalosporin Antibiotics Developed In The US.....II-48
Neosil Tests NEO 101 Antibiotic.....II-48
1$100
   New Antibiotic Developed By Canadian Inventors.....II-49
Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada.....II-49
Pencillin Binding Protein Found In Japan.....II-49
Venus Remedies Releases Mucomelt-Forte.....II-49
Baxter Launches Injectable Antibiotic, Zithromax.....II-49
Advancis Releases Keflex (750mg) Capsules.....II-49
1$100
   Researchers Develop Antibiotic For MRSA.....II-50
Wyeth Releases Tygacil In The UK.....II-50
Nihon Pharmaceutical Releases Clarithomycin Antibiotic.....II-50
Daiichi Sankyo Engages In Quinolone Antibiotic Development.....II-50
Shionogi Commercializes Finibax.....II-50
Sandoz and Nomura Phase4 Ventures Launch Nabriva Therapeutics Forschungs GmbH.....II-50
Lilly’s Investigational Cancer Agent Reaches Phase III Clinical Trial.....II-50
1$100
   Idemitsu Technofine Launches Antibacterial Product.....II-51
Galleon Develops Oral Aminoglycoside Antibiotic.....II-51
Advancis Introduces Keflex® Powder in the US.....II-51
Skin Test for Penicillin Comes Back into the Market.....II-51
1$100
   Cubist Introduces New Registry Program.....II-52
Idemitsu Technofine Launches Antibacterial Product.....II-52
1$100
  9. Focus on Select Global Players.....II-5310 $700  
   Abbott Laboratories (USA).....II-53
MiddleBrook™ Pharmaceuticals, Inc. (USA).....II-53
Bayer HealthCare AG (Germany).....II-53
1$100
   Bristol-Myers Squibb Co. (USA).....II-54
Cubist Pharmaceuticals, Inc. (USA).....II-54
Daiichi Sankyo Company, Limited (Japan).....II-54
1$100
   Eli Lilly and Co. (USA).....II-551$100
   GlaxoSmithKline Plc (UK).....II-56
Johnson & Johnson (USA).....II-56
1$100
   Kyorin Pharmaceutical Co., Ltd. (Japan).....II-57
LG Life Sciences Limited (Korea).....II-57
1$100
   MiddleBrook™ Pharmaceuticals, Inc. (USA).....II-58
Novartis AG (Switzerland).....II-58
1$100
   Pfizer Inc. (USA).....II-59
Pliva d.d. (Croatia).....II-59
1$100
   Roche (Switzerland).....II-60
Sanofi-Aventis SA (France).....II-60
Takeda Pharmaceutical Company, Ltd. (Japan).....II-60
1$100
   Toyama Chemical Co., Ltd. (Japan).....II-61
Wyeth Pharmaceuticals, Inc. (USA).....II-61
2$200
  10. Global Market Perspective.....II-63   
   Table 8: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-631$350
   Table 9: World Long-term Projections for Antibiotics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-641$350
   Table 10: World 10-Year Perspective for Antibiotics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-651$350
   Table 11: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-661$350
   Table 12: World Long-term Projections for Penicillin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-671$350
   Table 13: World 10-Year Perspective for Penicillin by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-681$350
   Table 14: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-691$350
   Table 15: World Long-term Projections for Cephalosporin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-701$350
   Table 16: World 10-Year Perspective for Cephalosporin by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-711$350
   Table 17: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-721$350
   Table 18: World Long-term Projections for Macrolides by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-731$350
   Table 19: World 10-Year Perspective for Macrolides by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-741$350
   Table 20: World Recent Past, Current & Future Analysis for Quinolones by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-751$350
   Table 21: World Long-term Projections for Quinolones by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-761$350
   Table 22: World 10-Year Perspective for Quinolones by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-771$350
   Table 23: World Recent Past, Current & Future Analysis for Carbapenems by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-781$350
   Table 24: World Long-term Projections for Carbapenems by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-791$350
   Table 25: World 10-Year Perspective for Carbapenems by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-801$350
   Table 26: World Recent Past, Current & Future Analysis for Other Antibiotics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-811$350
   Table 27: World Long-term Projectionsfor Other Antibiotics by Geographic Region – US, Canada, Jap an, Europe, Asia- Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-821$350
   Table 28: World 10-Year Perspective for Other Antibiotics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-831$350
III. MARKET87$1950
  1. The United States.....III-122 $1250  
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Antibiotics Approved Between 2000 and 2005 in the United States.....III-1
Competition.....III-1
1$75
   Table 29: Leading Players in the US Antibiotics Market (2006): Percentage Breakdown by Value Sales for Pfizer, Johnson & Johnson, GlaxoSmithKline, Abbott, and Others (includes corresponding Graph/Chart).....III-2
Strategic Corporate Developments.....III-2
8$750
   Product Introductions/Innovations.....III-102$150
   FDA Approvals / Patents.....III-124$300
   Focus on Select Players.....III-164$300
   B. Market Analytics.....III-20
Table 30: US Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-20
1$200
   Table 31: US Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-211$200
   Table 32: US 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-22
1$200
  2. Canada.....III-235 $575  
   Market Analysis.....III-23
Current And Future Analysis.....III-23
Strategic Corporate Developments.....III-23
1$75
   Product Introductions/Innovations.....III-24 1$75
   Table 33: Canadian Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-251$200
   Table 34: Canadian Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-261$200
   Table 35: Canadian 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-27
1$200
  3. Japan.....III-2810 $850  
   A. Market Analysis.....III-28
Current and Future Analysis.....III-28
Strategic Corporate Developments.....III-28
3$225
   Product Introductions/Innovations.....III-311$75
   Focus on Select Players.....III-323$225
   B. Market Analytics.....III-35
Table 36: Japanese Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-35
1$200
   Table 37: Japanese Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-361$200
   Table 38: Japanese 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-37
1$200
  4. Europe.....III-388 $850  
   A. Market Analysis.....III-38
Current and Future Analysis.....III-38
Strategic Corporate Developments.....III-38
2$150
   B. Market Analytics.....III-40
Table 39: European Recent Past, Current & Future Analysis for Antibiotics by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-40
1$200
   Table 40: European Long-term Projections for Antibiotics by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-411$200
   Table 41: European Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-421$200
   Table 42: European Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-431$200
   Table 43: European 10-Year Perspective for Antibiotics by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-441$200
   Table 44: European 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems, and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-45
1$200
  4a. France.....III-465 $525  
   A. Market Analysis.....III-46
Current and Future Analysis.....III-46
Trends.....III-46
Over Consumption of Antibiotics – Cause of Concern.....III-46
1$75
   Strategic Corporate Developments.....III-47
Sanofi-Aventis SA – A Key Player.....III-47
1$75
   B. Market Analytics.....III-48
Table 45: French Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-48
1$200
   Table 46: French Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-491$200
   Table 47: French 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-50
1$200
  4b. Germany.....III-515 $575  
   A. Market Analysis.....III-51
Current and Future Analysis.....III-51
Strategic Corporate Developments.....III-51
1$75
   Bayer HealthCare AG – A Key Player.....III-521$75
   B. Market Analytics.....III-53
Table 48: German Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-53
1$200
   Table 49: German Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-541$200
   Table 50: German 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-55
1$200
  4c. Italy.....III-564 $475  
   A. Market Analysis.....III-56
Current and Future Analysis.....III-56
Corporate Development.....III-56
1$75
   B. Market Analytics.....III-57
Table 51: Italian Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-57
1$200
   Table 52: Italian Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-581$200
   Table 53: Italian 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-59
1$200
  4d. The United Kingdom.....III-604 $425  
   Market Analysis.....III-60
Current And Future Analysis.....III-60
Product Introduction.....III-60
GlaxoSmithKline Plc – A Key Player.....III-60
1$75
   Table 54: UK Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-611$200
   Table 55: UK Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, acrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-621$200
   Table 56: UK 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-63
1$200
  4e. Spain.....III-643 $425  
   Market Analysis.....III-64
Table 57: Spanish Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-64
1$200
   Table 58: Spanish Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-651$200
   Table 59: Spanish 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-66
1$200
  4f. Rest of Europe.....III-677 $625  
   A. Market Analysis.....III-67
Current and Future Analysis.....III-67
Strategic Corporate Developments.....III-67
2$150
   Product Launch.....III-69
Focus on Select Players.....III-69
2$150
   B. Market Analytics.....III-71
Table 60: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-71
1$200
   Table 61: Rest of Europe Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-721$200
   Table 62: Rest of Europe 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-73
1$200
  5. Asia-Pacific.....III-7410 $850  
   A. Market Analysis.....III-74
Current and Future Analysis.....III-74
India.....III-74
Rising Prices of Penicillin G to Affect Antibiotics Production.....III-74
Strategic Corporate Developments.....III-74
5$375
   Product Introduction.....III-79
FDA Approvals / Patents.....III-79
Focus on Select Players.....III-79
2$150
   B. Market Analytics.....III-81
Table 63: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-81
1$200
   Table 64: Asia-Pacific Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-821$200
   Table 65: Asia-Pacific 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-83
1$200
  6. Rest of World.....III-844 $675  
   A. Market Analysis.....III-84
Current and Future Analysis.....III-84
Strategic Corporate Developments.....III-84
1$75
   B. Market Analytics.....III-85
Table 66: Rest of World Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-85
1$200
   Table 67: Rest of World Long-term Projections for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-861$200
   Table 68: Rest of World 10-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-871$200
IV. COMPETITIVE LANDSCAPE 505$995
  
Total Companies Profiled: 205 (including Divisions/Subsidiaries - 244)

Region/Country                 Players

The United States                 50
Canada                             8
Japan                             11
Europe                            65 
     France                        7
     Germany                      10
     The United Kingdom            8
     Italy                        10
     Spain                         4
     Rest of Europe               26 
Asia-Pacific (Excluding Japan)    95	
Middle East                       10
Latin America                      4
Africa                             1
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2009, Global Industry Analysts, Inc., USA.